ArriVent BioPharma Inc — Quarterly Cash Flow (NASDAQ:AVBP) | MetaTrader

Open full chart

Financials

Overview Rapor Statistics Dividends

Quarterly Annual

Total assets 292.71 M274.94 M215.5 M269.51 M326.56 M Total liabilities 15.22 M17.29 M12.95 M19.64 M21.56 M Total equity 277.49 M257.65 M202.54 M249.87 M305 M Total liabilities & shareholders' equities 292.71 M274.94 M215.5 M269.51 M326.56 M Total debt ————— Net debt —————

Haberler

Cantor Fitzgerald, ArriVent hissesi için Ağırlık Artırma notunu yineledi

ArriVent stock rating reiterated as Overweight by Cantor Fitzgerald

Oppenheimer, ArriVent BioPharma hissesi için Outperform notunu yineledi

Oppenheimer reiterates Outperform rating on ArriVent BioPharma stock

ArriVent BioPharma (AVBP): Its Leading Asset, Furmonertinib, Supports A Cautious Buy

ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts (NASDAQ:AVBP)

Cantor Fitzgerald, ArriVent BioPharma hissesini Ağırlık Üstü tavsiyesiyle takibe aldı

Cantor Fitzgerald initiates ArriVent BioPharma stock with Overweight rating

ArriVent, akciğer kanseri ilacı için önemli faz 3 çalışmasında ilk hastaya doz verdi

ArriVent doses first patient in pivotal phase 3 trial for lung cancer drug

BTIG, ArriVent BioPharma’ya onkoloji potansiyeli nedeniyle Al tavsiyesi verdi

ArriVent BioPharma stock initiated with Buy rating at BTIG on oncology potential